We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Rheumatology

Rheumatology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

A Novel Weighted Flare Score Enhances Prediction of Organ Damage in Systemic Lupus Erythematosus
Rheumatologytreat-to-targetsystemic lupus erythematosus

A Novel Weighted Flare Score Enhances Prediction of Organ Damage in Systemic Lupus Erythematosus

By MedXY|Oct 19, 2026

A newly developed weighted flare scoring system in SLE accurately predicts organ damage accumulation, outperforming traditional flare classifications and informing treat-to-target strategies.

Centralized Expert Review Enhances Diagnostic Accuracy in Axial Spondyloarthritis: Insights from a Multicenter Telemedicine Study
newstelemedicinemulticenter study

Centralized Expert Review Enhances Diagnostic Accuracy in Axial Spondyloarthritis: Insights from a Multicenter Telemedicine Study

By MedXY|Oct 18, 2026

Centralized clinical and imaging evaluation via telemedicine significantly improves diagnostic accuracy in patients suspected of axial spondyloarthritis, reducing misdiagnoses and guiding more precise patient management.

Phenotype-Specific Mosaic Chromosomal Alterations in Systemic Sclerosis: Implications for Disease Subtypes and Clinical Outcomes
Hematology-Oncologymosaic chromosomal alterationssystemic sclerosis

Phenotype-Specific Mosaic Chromosomal Alterations in Systemic Sclerosis: Implications for Disease Subtypes and Clinical Outcomes

By MedXY|Oct 17, 2026

This article explores the differential associations of mosaic chromosomal alterations (mCAs), especially chromosomal loss and mosaic loss of the X chromosome, with systemic sclerosis and its subtypes, revealing phenotype-specific genetic co

Inducible Laryngeal Obstruction in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Clinical Correlates and Predictors
newshypermobile Ehlers-Danlos syndromehypermobility spectrum disorders

Inducible Laryngeal Obstruction in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Clinical Correlates and Predictors

By MedXY|Oct 17, 2026

This study explores the association between inducible laryngeal obstruction (ILO) and symptoms in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD), highlighting chronic cough, dysphagia, and

Quality indicators for lupus nephritis care: implementing the 2025 EULAR recommendations — development, adherence, and impact on outcomes
Nephrologyclinical outcomesEULAR 2025

Quality indicators for lupus nephritis care: implementing the 2025 EULAR recommendations — development, adherence, and impact on outcomes

By MedXY|Oct 16, 2026

A validated set of 17 quality indicators (QIs) for lupus nephritis, derived from the 2025 EULAR recommendations, shows variable adherence in practice and an association between higher adherence and lower damage accrual in a tertiary-care co

IgG4-Related Disease Shows No Increased Risk of Malignancy: Insights from a Large Cohort Study
newsAutoimmune diseasebệnh liên quan đến IgG4

IgG4-Related Disease Shows No Increased Risk of Malignancy: Insights from a Large Cohort Study

By MedXY|Oct 15, 2026

A large single-center cohort study found no increased incidence of malignancy in patients with IgG4-related disease (IgG4-RD). Smoking and older age increased malignancy risk, while female sex and submandibular gland involvement were protec

What’s New in EULAR’s 2026 SOPs: How Rheumatology Guidelines Will Be Built from Now On
newsEULARguideline methodology

What’s New in EULAR’s 2026 SOPs: How Rheumatology Guidelines Will Be Built from Now On

By MedXY|Oct 14, 2026

The 2026 EULAR update modernizes how recommendations and points-to-consider for rheumatic and musculoskeletal diseases are developed — formalizing patient partnership, living guidance, robust evidence synthesis, cost-awareness and transpare

Impact of Air Pollution on Rheumatoid Arthritis Activity: Insights from a Prospective Cohort Study
newsair pollutiondisease activity

Impact of Air Pollution on Rheumatoid Arthritis Activity: Insights from a Prospective Cohort Study

By MedXY|Oct 13, 2026

This study reveals that exposure to fine particulate matter (PM2.5) significantly increases disease activity and flare risk in rheumatoid arthritis patients, highlighting the importance of air quality in disease management.

Evaluating Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease: Insights from a Multicenter Retrospective Study
newsAzathioprinefibrotic interstitial lung disease

Evaluating Mycophenolate and Azathioprine in Fibrotic Interstitial Lung Disease: Insights from a Multicenter Retrospective Study

By MedXY|Oct 8, 2026

This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressi

Predicting Two-Year Relapse Risk in ANCA-Associated Vasculitis: Insights from the PEXIVAS Trial
NephrologyANCA-Associated VasculitisPEXIVAS trial

Predicting Two-Year Relapse Risk in ANCA-Associated Vasculitis: Insights from the PEXIVAS Trial

By MedXY|Oct 2, 2026

A risk prediction model derived from the PEXIVAS trial estimates the 2-year relapse probability in ANCA-associated vasculitis, integrating clinical and laboratory factors to improve individualized patient management.

Molecular Biomarkers Predicting Canakinumab Tapering Success in Systemic Juvenile Idiopathic Arthritis
newsbiomarkercanakinumab

Molecular Biomarkers Predicting Canakinumab Tapering Success in Systemic Juvenile Idiopathic Arthritis

By MedXY|Oct 2, 2026

This study identifies serum and gene expression signatures predicting successful canakinumab tapering in systemic juvenile idiopathic arthritis, offering precision medicine strategies to reduce flares.

Distinct Pustular Psoriasis Flares After Biologic Withdrawal in Plaque Psoriasis: Clinical Features and Risk Factors
Dermatologybiologic withdrawalplaque psoriasis

Distinct Pustular Psoriasis Flares After Biologic Withdrawal in Plaque Psoriasis: Clinical Features and Risk Factors

By MedXY|Oct 2, 2026

This multicenter study identifies a unique pustular psoriasis flare phenotype occurring after biologic therapy withdrawal in plaque psoriasis, detailing clinical characteristics and independent risk factors to guide vigilant monitoring and

Imaging Biomarkers Predicting Inflammatory Arthritis in Anti-CCP Positive Patients Without Clinical Synovitis
newsanti-CCPMRI

Imaging Biomarkers Predicting Inflammatory Arthritis in Anti-CCP Positive Patients Without Clinical Synovitis

By MedXY|Oct 2, 2026

MRI-detected hand tenosynovitis and ultrasound-detected bone erosions independently and jointly predict progression to inflammatory arthritis in anti-CCP positive individuals with musculoskeletal symptoms but no clinical synovitis.

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies
Clinical Updatessystemic lupus erythematosusimmunotherapy

Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

By MedXY|Sep 22, 2026

Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.

Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target
Hematology-OncologyI型インターフェロンHemophilia A

Unraveling Neutrophil-Driven Interferonopathy in Hemophilic Arthropathy: A New Therapeutic Target

By MedXY|Sep 20, 2026

This study identifies neutrophil-dependent type-I interferon responses and NETs as key drivers of joint damage in hemophilia A, opening avenues for novel therapies to prevent hemophilic arthropathy.

Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia
Diabetes & EndocrinologyDietary patternsgout flare

Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia

By MedXY|Sep 17, 2026

A 12-week randomized trial compared the effects of calorie-restricted DASH, carbohydrate-restricted, and low-purine diets on weight loss and serum urate levels in men with overweight or obesity and hyperuricemia, highlighting adherence and

IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial
Neurologyprednisonerandomized clinical trial

IVIG Plus Prednisone Enhances Recovery in Newly Diagnosed Idiopathic Inflammatory Myopathies: Insights from a Randomized Clinical Trial

By MedXY|Sep 16, 2026

A recent randomized trial shows that adding intravenous immunoglobulin (IVIG) to high-dose prednisone significantly improves muscle strength and disease activity in newly diagnosed idiopathic inflammatory myopathies with rapid and clinicall

Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French Cohort
Cardiologytocilizumabcardiovascular risk

Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French Cohort

By MedXY|Sep 8, 2026

A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation contr

Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus
newssystemic lupus erythematosuspharmacodynamics

Targeting TYK2 with Deucravacitinib: Pharmacodynamic Insights from the Phase 2 PAISLEY Trial in Systemic Lupus Erythematosus

By MedXY|Sep 4, 2026

Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.

Parenteral vs Oral Glucocorticoids in Early Rheumatoid Arthritis: Impact on Steroid Discontinuation and Therapy Escalation at One Year
newsrheumatoid arthritisparenteral administration

Parenteral vs Oral Glucocorticoids in Early Rheumatoid Arthritis: Impact on Steroid Discontinuation and Therapy Escalation at One Year

By MedXY|Sep 4, 2026

This study assesses whether the administration route of glucocorticoids in early rheumatoid arthritis influences continued steroid use and advanced therapy initiation at one year.

1 / 7
123…7
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Browse by specialty

Open language-specific specialty feeds and department pages.

news7286 articlesCardiology1448 articlesClinical Updates1367 articlesOncology1248 articlesDiabetes & Endocrinology924 articlesNeurology883 articlesPublic Health635 articlesGastroenterology618 articles
Hematology-Oncology
559 articles
Pediatrics533 articles
Internal Medicine483 articles